
To evaluate the safety and efficacy of zzso during 2 years of the zzso zzso Trial in Treatment of zzso zzso zzso trial in patients with zzso zzso 

Patients completing the zzso zzso period were eligible to enter the long-term zzso patients received zzso approximately 10 zzso plus zzso zzso zzso Safety and efficacy (American College of zzso zzso criteria responses, zzso zzso zzso zzso zzso Medical Outcomes Study Sleep zzso Index, fatigue zzso were assessed through 2 zzso 

317 patients zzso from the zzso and 99 from the zzso zzso entered and 222 zzso completed 18 months of long-term extension zzso The zzso and type of adverse events were consistent between the zzso and cumulative zzso plus long-term zzso zzso Rates of serious adverse events were zzso and zzso per 100 zzso in the zzso versus cumulative zzso At 6 months and 2 years, using zzso zzso zzso responses in zzso patients were: zzso 20, zzso and zzso zzso 50, zzso and zzso zzso 70, zzso and zzso zzso responses were zzso and zzso At 6 months and 2 years, using zzso zzso zzso the percentage of patients zzso confidence zzso achieving zzso zzso zzso low disease activity score zzso or zzso zzso and zzso zzso zzso zzso zzso zzso increased from zzso zzso zzso to zzso zzso zzso and zzso zzso zzso to zzso zzso zzso zzso meaningful improvements in zzso pain, fatigue and sleep problems were also maintained throughout the 2 years of zzso zzso 

No unique safety observations were reported during zzso zzso zzso in the signs and symptoms of zzso arthritis, physical function and zzso quality of life observed after 6 months, were maintained throughout the 2 years in this population with zzso zzso 

zzso 

